Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: New dosing schedules of dasatinib for CML and adverse event management | BioMed Central Journal of Hematology Oncology Open Access Review New dosing schedules of dasatinib for CML and adverse event management Siu-Fun Wong Address Western University of Health Sciences College of Pharmacy Pomona CA USA Email Siu-Fun Wong - siuwong@westernu.edu Published 23 February 2009 Received 9 December 2008 Journal of Hematology Oncology 2009 2 10 doi 10.1186 1756-8722-2-10 Accepted 23 February 2009 This article is available from http www.jhoonline.Org content 2 1 10 2009 Wong licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Resistance to imatinib in patients with chronic myelogenous leukemia CML or Philadelphia chromosome-positive acute lymphoblastic leukemia Ph ALL has emerged as a significant clinical issue. Dasatinib is a tyrosine kinase inhibitor that has 325-fold greater in vitro activity against native BCR-ABL breakpoint cluster region-Abelson leukemia virus compared with imatinib and can overcome primary intrinsic and secondary acquired imatinib resistance. Here we review the clinical profile of dasatinib in imatinib-resistant and -intolerant patients and share clinical approaches for managing adverse events AEs to ensure maximum patient benefit. References were obtained through literature searches on PubMed as well as from the Proceedings of Annual Meetings of the American Society of Clinical Oncology the American Society of Hematology and European Hematology Association. Phase II and III studies of dasatinib in patients with imatinib-resistant or -intolerant CML in any phase or Ph ALL were selected for discussion. Dasatinib is currently indicated for the treatment of patients with imatinib-resistant or -intolerant CML or Ph ALL. AEs associated with dasatinib are typically mild to moderate and
